# Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

> **NCT02187627** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 52 (actual)

## Conditions studied

- Alzheimer's Disease, Healthy Volunteer

## Interventions

- **DRUG:** [11C]RO6924963
- **DRUG:** [11C]RO6931643
- **DRUG:** [18F]RO6958948

## Key facts

- **NCT ID:** NCT02187627
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-31
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187627, "Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02187627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*